OTC : LZAGF

Lonza Group AG

$675.41 USD

$10 (1.5%)

Volume
9
Average Volume
388
Market Capitalization
$47.17B
P/E Ratio
-355.84
Dividend Yield
0.91%
Price Target
Year High
$755.96
Year Low
$565.14
Day High
—
Day Low
—
Payout Ratio
-$3.39
Current Ratio
$1.66
Company Overview

OTC

Wolfgang Wienand

Medical - Diagnostics & Research

Healthcare

LZAGF

17995

CH

USD

https://www.lonza.com

41 61 316 81 11

N/A

N/A

Liquidity Metrics

0.51

1.66

1.21

0.12

-3.39

Sales & Valuation

$6.53B

6.05

4.71

234.81

2.33

Profitability

$13.51

$949M

-1.74%

20.29%

-1.28%

-0.60%

P/E Metrics

-355.84

2.22

2.22

Analyst Price Target & Rating

Sell

2/5

1 Analysts

%

Financial Health Scores

4.25

7/9

$2.76B

$18.26B

$10.11B

$2.34B

Key Metrics (TTM)

$41.95B

6.63

21.35

1.66

-1.28%

8.06%

-0.29%

0.43%

280 days

Company Executives
Name Title
Nicoleta Baumgartner Chief Human Resources Officer
Victoria Morgan Head of External Communications
Christian Seufert President of Capsules & Health Ingredients Division
Gordon Bates President of Small Molecules Division
Jean-Christophe Hyvert President of Biologics Division
David Carter Head of Communications
Matthias Hofmann Head of Corporate Environment, Health, Safety & Global Sustainability
Jennifer Clancy Senior Director of Global Marketing
Kim Harrelson Head of Ethics & Compliance, ERM and Corporate Responsibility
Wolfgang Wienand Chief Executive Officer
Andreas Bohrer Chief Legal & Corporate Affairs Officer
Jason Berndt Executive Vice President & Head of Group Operations
Philippe Deecke Chief Financial Officer
Daniel Buchta Head of Investor Relations
Poll Results

No votes yet today — be the first to share your view!

About Lonza Group AG (OTC:LZAGF) Stock

Lonza Group AG, established in 1897 and based in Basel, Switzerland, is a global enterprise that furnishes critical products and services to the pharmaceutical, biotechnology, and nutrition sectors. Its operational footprint extends across Europe, North and Central America, Latin America, Asia, Australia, New Zealand, and beyond. The company's activities are organized into four primary divisions: Biologics: This segment is dedicated to the contract development and manufacturing (CDMO) of biopharmaceuticals, offering extensive support for both drug substances and finished drug products throughout their entire lifecycle, from clinical trials to commercial-scale production. Small Molecules: Operating as a fully integrated service provider, this division handles the development and manufacturi ... ng of small molecule active pharmaceutical ingredients and their intermediate compounds, guiding clients through all stages of design, development, and production. Cell & Gene: This segment focuses on advancing technologies and platforms to industrialize the manufacturing processes of cell and gene therapies. It also provides comprehensive contract development, manufacturing, and regulatory guidance for a diverse range of allogeneic and autologous cell therapies, exosome-based treatments, and viral vector gene therapies. Additionally, it supplies specialized raw materials and enabling technological solutions vital for cell and gene therapy, injectable medications, vaccines, and biomanufacturing markets. Capsules & Health Ingredients: This division delivers various capsules, innovative dosage form solutions, and health-promoting ingredients to pharmaceutical and nutraceutical customers.

Lonza: Strong H1 Execution, Higher Guidance Means Higher Upside

2026-07-22 22:46:52

H1 results showed 16% sales growth, a 44% net profit increase, and EBITDA margin expansion to 34.8%, driven by higher asset utilization and segment outperformance. Integrated Biologics, Advanced Synthesis, and Specialized Modalities each delivered double-digit growth. Management raised its 2026 CORE EBITDA margin outlook to 33–34% while maintaining 11–12% sales growth guidance. Our buy rating is confirmed.

Lonza Group AG (LZAGY) Q1 2026 Earnings Call Transcript

2026-05-08 14:51:19

Lonza Group AG (LZAGY) Q1 2026 Earnings Call Transcript

Frequently Asked Questions

What is the current Lonza Group AG (LZAGF) stock price?

Lonza Group AG(OTC:LZAGF) stock price is $675.41 in the last trading session. During the trading session, LZAGF stock reached the peak price of $755.96 while $565.14 was the lowest point it dropped to. The percentage change in LZAGF stock occurred in the recent session was 1.5% while the dollar amount for the price change in LZAGF stock was $10.

LZAGF's industry and sector of operation?

The OTC listed LZAGF is part of Medical - Diagnostics & Research industry that operates in the broader Healthcare sector.

Who are the executives of LZAGF?

Nicoleta Baumgartner | Chief Human Resources Officer
Victoria Morgan | Head of External Communications
Christian Seufert | President of Capsules & Health Ingredients Division
Gordon Bates | President of Small Molecules Division
Jean-Christophe Hyvert | President of Biologics Division

How many employees does LZAGF have?

Number of LZAGF employees currently stands at 17995. LZAGF operates from Muenchensteinerstrasse 38, Basel, BS 4002, CH.

Link for LZAGF official website?

Official Website of LZAGF is: https://www.lonza.com

How do I contact LZAGF?

LZAGF could be contacted at phone #41 61 316 81 11 and can also be accessed through its website. LZAGF operates from Muenchensteinerstrasse 38, Basel, BS 4002, CH.

How many shares of LZAGF are traded daily?

The average number of LZAGF shares traded daily for last 3 months was 388.

What is the market cap of LZAGF currently?

The market value of LZAGF currently stands at $47.17B with its latest stock price at $675.41